Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking

Ming NIU; Rui-Lin WANG; Zhong-Xia WANG; Ping ZHANG; Zhao-Fang BAI; Jing JING; Yu-Ming GUO; Xu ZHAO; Xiao-Yan ZHAN; Zi-Teng ZHANG; Xue-Ai SONG; En-Qiang QIN; Jia-Bo WANG; Xiao-He XIAO.
China Journal of Chinese Materia Medica ; (24): 1213-1218, 2020.
Artículo en Zh | WPRIM | ID: wpr-1008558

Documentos relacionados

  1. [Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].
  2. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
  3. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
  4. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.
  5. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.
  6. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor.
  7. Structural basis of receptor recognition by SARS-CoV-2.
  8. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
  9. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
  10. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.